-
Gilead Seeks Diversification Into Immuno-oncology Space With $11.9 Billion Kite Pharma Acquisition
Monday, August 28, 2017 - 8:59am | 504Read More...In a major push into the immuno-oncology space, Gilead Sciences, Inc. (NASDAQ: GILD), which is primarily into antiviral drug development, specifically for the treatment of HIV, hepatitis B, hepatitis C and influenza, announced a multi-billion dollar deal to buy Kite Pharma Inc (NASDAQ: KITE...
-
Gilead Hits New 52-Week Low; Here Are Two Reasons Why
Friday, January 29, 2016 - 2:32pm | 203Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) lost more than 5 percent on Friday and hit a new 52-week low of $82.41 after the company announced a change to its senior leadership. Effective March 10, 2016, Gilead's current Chairman and CEO John Martin will assume the role of Executive...
-
Gilead's President Spoke At Goldman Sachs' Global Healthcare Conference This Week: Here Are The Highlights
Thursday, June 11, 2015 - 2:00pm | 794Read More...Gilead Sciences, Inc. (NASDAQ: GILD) President and COO John Milligan spoke to investors at Goldman Sachs' annual Global Healthcare Conference on Tuesday. He addressed the biotech company's growth, drug portfolio, and future prospects. A Good Year Milligan discussed how Gilead's...
-
Deutsche Bank Comments On Gilead Sciences Client Dinner
Tuesday, May 3, 2011 - 9:01am | 140Read More...According to Deutsche Bank, it met with Gilead Sciences (NASDAQ: GILD) management. Deutsche Bank said that it hosted a client dinner with COO John Milligan last night. “Co sees B-tripla as potentially being the "kindler gentler Atripla," with potential for uptake where Sustiva is not preferred....
